Aldeyra Therapeutics (ALDX) Jefferies London Healthcare Conference 2024 summary

Company overview and recent developments

• Focuses on immunology and inflammation (I&I) with late-stage lead candidate for dry eye disease under NDA review and option agreement with AbbVie.

• PDUFA date for lead drug is set for April 2, 2025, with high hopes for approval following a successful additional clinical trial.

• AbbVie holds co-promotion rights for all indications, with significant milestone payments and profit-sharing structure.

• Pipeline includes candidates for allergic conjunctivitis, atopic dermatitis, alcoholic hepatitis, and retinal diseases.

• Financially well-positioned with $113 million in cash and potential for $194 million in milestones upon approval.

Lead product: Reproxalap for dry eye disease

• Addressed FDA's request for an additional trial, which showed highly significant results and led to NDA resubmission.

• Draft label includes two signs (notably ocular redness) and two symptoms, aiming for differentiation from competitors.

• Only chronic-use drug candidate with redness reduction on the label, a key market differentiator.

• Demonstrated rapid onset of action in dry eye chamber studies, showing improvement in minutes.

• AbbVie expected to lead commercialization efforts if approved, leveraging their expertise in eye care.

Market opportunity and positioning

• Dry eye disease market is large and growing, driven by increased screen time and aging population.

• Reproxalap's rapid efficacy and unique label features position it strongly against existing therapies.

• Significant overlap between dry eye and allergic conjunctivitis broadens addressable market.

• Plans to pursue supplemental NDA for allergic conjunctivitis to further expand market reach.